GSK is currently the market leader in the meningococcal vaccine market, racking up sales of £1.26 billion (almost $1.6 billion) last year across the Bexsero and Menveo brands, but is having to ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya.

Since the rollout of the conjugate MenC vaccine in 2001 and the MenACWY in 2018, rates of invasive meningococcal disease have ...

Two Tasmanian women have been hospitalized with invasive meningococcal disease, bringing the number of cases nationally so ...

Asked by LaPook what the federal government's official position on the vaccine is, Kennedy reiterated, "The federal government's position, my position, is that people should get the measles ...